Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis

K W Drossaers-Bakker, A H Zwinderman, D van Zeben, F C Breedveld, J M W Hazes

Background: Oral contraceptives (OC) and pregnancy are known to have an influence on the risk of onset of rheumatoid arthritis (RA). Pregnancy itself has beneficial effects on the activity of the disease, with relapses post partum. It is not known, however, whether OC and pregnancies influence the ultimate outcome of RA.

Objectives: To explore whether OC use and pregnancies influence the 12 year outcome in RA as measured by radiological damage and disability.

Methods: In a prospective inception cohort of 132 female patients with recent RA according to the 1987 American College of Rheumatology criteria—a cohort initially gathered to study the association between hormonal factors and the onset of RA—outcome was assessed in a follow up after 12 years. The outcome was evaluated in 112 (85%) women by the radiological damage of hands and feet as measured with the Sharp score modification van der Heijde (SHS), the damage of the large joints measured with the Larsen score (LS) of large joints (0–60), and the disability measured with the Health Assessment Questionnaire (HAQ). The median values of each outcome variable were calculated for several subgroups of patients stratified for OC use and pregnancies before and after onset of the disease and the tertiles of the total number of months of OC use and of pregnancies. The association of OC use and pregnancies before and after onset of the disease with the outcome variables was calculated using Spearman’s rank correlation ($r$). The combined influence of OC use and pregnancies on the SHS, LS, and HAQ at 12 years was estimated using ordinal polytomous logistic regression.

Results: The median values of the SHS, LS, and HAQ showed a trend towards less radiological joint damage and less disability in women with long term OC use and multiple pregnancies. This difference, however, was not significant, except for the HAQ score in women with three or more pregnancies in life. There was no association between pregnancies, however defined, and any parameter of RA outcome after 12 years (maximum $r_m=-0.10$). The only significant correlation was found between OC use before symptom onset and the LS ($r_m=-0.22$, $p<0.05$). The combination of hormonal variables explained no more than a maximum of 3% of the variance of the 12 year outcome as measured by the SHS.

Conclusion: OC use and pregnancy do not significantly influence outcome in long term RA. There is, however, a trend for patients with multiple pregnancies and long term OC use to have less radiographic joint damage and a better functional level.

The relationship between rheumatoid arthritis (RA) and female sex hormones has long intrigued clinicians. There is a dual relationship between the two. Women, particularly women in their reproductive years, are more susceptible to RA than men. On the other hand, it has been suggested that the onset of RA is postponed by parity, the risk of onset is reduced during pregnancy, while in the first year post partum the chance of onset is increased. Moreover, the disease itself is also influenced by pregnancy. Several studies showed that disease activity decreased in 50–75% of women with RA during pregnancy, 16% even achieved complete remission, and many were able to stop all drugs by the last trimester. After delivery, disease activity predictably returned.

An explanation for the amelioration of the disease activity during pregnancy may be the increased immune tolerance during that period. The immunological changes related to pregnancy are thought to be due to the maternal exposure to fetal (paternal) antigens. Nelson et al noted an increased number of HLA class II incompatibilities between mother and child among women with diminished activity of RA during pregnancy. Moreover, a shift towards Th2 cells was seen during pregnancy, which also might influence the level of disease activity.

The overall effect of the changes during gestation and post partum on long term outcome in RA is insufficiently known. One retrospective analysis showed no influence of pregnancy on functional capacity, disease activity, erosive arthritis, and erythrocyte sedimentation rate (ESR) in a long term follow up. As far as we know, no prospective data on the effect of pregnancy on long term outcome in RA are available. Several mechanisms have been proposed to explain the influence of female sex hormones on the onset and course of RA. Studies in vivo and in vitro have shown that sex hormones interfere with immunoregulation, interact with inflammatory mediators, and have direct effects on the cartilage itself. All these observations point towards the importance of gonadal hormones in immunoregulation.

Oral contraceptives (OC) have been thought to protect against the more severe forms of RA. The influence of OC use on the long term outcome in RA is not known.

The aim of the present study was twofold. Firstly, to study whether OC use or pregnancies before and after onset of RA are associated with long term radiological joint damage or...
disability; and, secondly, to estimate the combined influence of OC use and pregnancies on radiological joint damage and disability.

**PATIENTS AND METHODS**

**Patients**

The present patient cohort has been extensively described in previous reports. The patients were gathered together for a case-control study of the association between hormonal factors and RA. In total, 138 consecutive incident female patients with RA visiting the outpatient rheumatology clinic of the Leiden University Medical Centre for the first time between 1982 and 1986 with symptoms of recent onset (0–5 years) and aged 20–50 years at first visit were included in the study. Of the 138 patients invited to participate, three initially refused to cooperate and three were lost during the first years as they moved out of the area. One hundred and thirty two women were prospectively followed up for 12 years. Data were collected at the start of the study, yearly in the first six years and, finally, at the follow up after 12 years. Because the patients had their final assessment done over a two year period, not all patients were assessed at exactly 12 years of follow up. The median disease duration at the last follow up visit was 12 years (range 10–14). This final assessment will be referred to as the 12 year follow up assessment.

**Hormonal factors**

At the start of the study detailed information on OC use was collected, including dates and duration of use in monthly periods. A life calendar with major life events when contraceptive use might begin (for example, engagement, marriage, childbirth) and a tray with examples of OC packages available in the Netherlands from 1960 to that date were used to help women recall their use of contraceptives. The records of their general practitioners were checked if a patient could not give complete information. Pregnancies before the onset of RA were recorded. At all assessments the number of months of OC use and the number of pregnancies during the previous period were recorded.

**Disease activity**

At baseline the number of swollen joints, the Ritchie articular index, and the Westergren ESR scores were obtained as parameters of disease activity. The disease activity score (a pooled index of the ESR, the number of swollen joints, and the Ritchie articular index) was calculated as a combined index of disease activity.

**Radiology**

Radiographs of the hands and feet were taken at study start and after 12 years of follow up and scored using the Sharp score modification van der Heijde (SHS). The SHS separately identifies joint space narrowing (JSN) and erosions in the metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints and two interphalangeal joints of the big toes. The joint of the thumb has only an erosion score. Furthermore, six areas in each wrist are assessed for JSN and the Ritchie articular index was calculated as a combined index of disease activity.

**Physical functioning**

The Health Assessment Questionnaire (HAQ) is used as the parameter for physical functioning and was adapted for the Dutch population. The questionnaire consists of eight categories and the responses are scored on a four point scale. The questionnaire has a final column in which respondents can indicate the use of any aid or device. The use of one of these is scored by at least a 2. The highest score of each category is taken as the score for that category. The final score of the questionnaire is the averaged score of all the categories, and ranges between 0 and 3.

**Analysis**

To see whether there were baseline differences between patients with or without OC use or with or without pregnancies, the baseline variables were compared between these groups of patients. Differences were tested for significance using Student’s t test or Mann-Whitney test, where appropriate.

Outcome at 12 years was also compared between these subgroups. In addition, the effects on outcome of pregnancies and OC use before RA onset, and during RA were evaluated.

The effect of OC use and pregnancies on outcome was further studied by separating the sample into subgroups of patients based on the tertiles of total months of OC use and on the tertiles of the number of pregnancies. In all cases we used non-parametric test statistics.

Finally, Spearman rank correlations and ordinal polytomous logistic regression were used to analyse the association between outcome variables and several hormonal parameters.

**RESULTS**

Table 1 shows the demographic and baseline variables. There were no statistically significant differences between the groups except for the age of disease onset between patients with or without OC use. Furthermore, there was also no difference in baseline variables, including OC use and pregnancies, between the women studied and those lost to follow up.

The median duration of OC use before the onset of RA was 60 months (range 0–248) and during the course of the RA the median duration of OC use was 34 months (0–144). The median of the total duration of OC use was 94 months (0–392). The median number of pregnancies was 2 (0–8) before the onset of RA and 0 (0–4) during the course of RA. The median of the total of pregnancies was 2 (0–8).

<table>
<thead>
<tr>
<th>Parity ever</th>
<th>OC use ever</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Number of patients</td>
<td>21</td>
</tr>
<tr>
<td>Age</td>
<td>39 (9.4)</td>
</tr>
<tr>
<td>Duration symptoms</td>
<td>1 (2.7)</td>
</tr>
<tr>
<td>DAS</td>
<td>3.0 (1.5)</td>
</tr>
<tr>
<td>RF positive (%)</td>
<td>71</td>
</tr>
<tr>
<td>SHS</td>
<td>0.8 (7.8)</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.88 (1.5)</td>
</tr>
</tbody>
</table>

DAS, disease activity scale; RF, rheumatoid factor; SHS, Sharp score modification van der Heijde; HAQ, Health Assessment Questionnaire.

*p<0.02, Mann-Whitney.
The association became non-significant. After checking for age, rheumatoid factor, and SHS at onset, RA with the LS of large joints was statistically significant. Calculated. Only the association of OC use before the onset of pregnancy three or more times had significantly less disability damage and less disability. Patients who had been pregnant had less disability in the four subgroups of patients. The Spearman rank correlations of the outcome parameters for radiographic joint damage and disability as measured by the HAQ was less in the group with OC use than those who had not been pregnant.

Table 2 shows the outcome variables for radiographic joint damage and disability in the four subgroups of patients. The patients who either used OC or had been pregnant had less radiographic joint damage of the small and large joints, but this difference did not reach statistical significance. Disability as measured by the HAQ was less in the group with OC use and pregnancies; in the group of women who had been pregnant before the onset of RA the difference in HAQ was the largest (0.38).

By further study possible differences in outcome between groups, the medians of the SHS, Larsen, and HAQ, were calculated for each tertile of cumulative OC use and of cumulative pregnancies (table 3). Again the patients within the highest tertile of pregnancies or months of OC use had less radiological damage and less disability. Patients who had been pregnant three or more times had significantly less disability than those who had not been pregnant.

The Spearman rank correlations of the outcome parameters with the exposure to pregnancy or cumulative OC use were calculated. Only the association of OC use before the onset of RA with the LS of large joints was statistically significant. After checking for age, rheumatoid factor, and SHS at onset, the association became non-significant.

When polytomous logistic regression analysis on the tertiles of the SHS distribution was used, the (pseudo) $R^2$ of the combined influence of OC use and pregnancies was only 0.026. Neither number of pregnancies (odds ratio (OR)=0.96, $p=0.70$) nor months of OC use (OR=0.99, $p=0.11$) were significantly related to SHS tertile.

**DISCUSSION**

This study shows that OC use and pregnancy only minimally influence the long term outcome in RA as assessed by joint damage and disability. There is, however, a trend towards less joint damage and disability in patients with long term OC use and multiple pregnancies.

The study shows that the median HAQ score in women with a total of two pregnancies during life is 0.63 lower than the score in women with no child or one. A difference between HAQ scores of more than 0.2 is considered clinically relevant. The trend towards less radiographic joint damage and less disability in women with long OC use is noticeable because the women in the OC use group were significantly older than the group without OC use. Disability in RA has been shown to be greater in older patients, so the trend towards less disability in the older patients with long OC use is even more remarkable. Disease modifying drug (DMARD) use influences outcome and was shown to have a beneficial effect on radiographic damage and function. All women were similarly treated by the less aggressive standard of two decades ago. Women who wanted to get pregnant often discontinued drug treatment. Therefore the trend towards less radiographic damage and disability is not likely to be due to DMARD use. The trend towards a milder disease in the group of patients with a high exposure to female sex hormones, however, did not show statistical significance, which might be owing to a lack of power. This is not surprising considering the large ranges of the outcome variables (table 2 and 3). Three hundred and thirty female patients divided into two subgroups would be needed to reach statistical significance, given the data of the present study and the trend found. In the univariate analysis the associations were not strong. Moreover, in a multivariate analysis the combined influence of OC use and pregnancies explained no more than at most 4% of the variance of the 12 year outcome as measured by the SHS, LS, or HAQ.

Pregnancy was first reported to induce remission in RA in 1935. Since then, many studies have reported the ameliorating effect of pregnancy on disease activity. As a possible explanation for this phenomenon it has been suggested that levels of endogenous female hormones influence the disease. This

| Table 2 | Median values [range] of the outcome variables for radiographic joint damage as measured with the SHS and Larsen score of large joints and disability as measured with the HAQ in subgroups with respect to OC use and pregnancies before and during RA in female patients at 12 years of follow up |
|---|---|---|---|
| Number of patients | SHS | Larsen | HAQ |
| OC use before RA* | 30 | 148 (0–392) | 6.5 (0–34) | 1.0 (0–2.63) |
| + | 62 | 117 (0–428) | 3.0 (0–55) | 0.87 (0–3) |
| OC use during RA* | - | 146 (0–392) | 5.0 (0–48) | 1.0 (0–2.88) |
| + | 78 (0–428) | 3.0 (0–55) | 0.75 (0–3) |
| Pregnant before RA* | - | 145 (0–413) | 3.0 (0–48) | 1.0 (0–2.88) |
| + | 123 (0–428) | 3.0 (0–55) | 0.62 (0–3) |
| Pregnant during RA* | - | 145 (0–428) | 3.0 (0–55) | 1.0 (0–3) |
| + | 56 (0–395) | 3.0 (0–31) | 0.87 (0–2.25) |

SHS, Sharp score modification van der Heijde; Larsen, Larsen score for large joints (0–60); HAQ, Health Assessment Questionnaire.

*p Differences between – and + not significant according to Mann-Whitney.

| Table 3 | Median values [range] of the outcome variables for radiographic joint damage as measured with the SHS and Larsen score for large joints and disability as measured with the HAQ in subgroups with respect to tertiles of exposure to OC use in months and number of pregnancies in female patients with RA at 12 years of follow up |
|---|---|---|---|
| Number of patients | SHS | HAQ | Larsen |
| Total OC use | | | |
| <40 months | 37 | 146 (0–392) | 1.0 (0–2.63) | 6 (0–48) |
| 40<x<150 | 36 | 157 (0–395) | 0.87 (0–2.88) | 2.5 (0–55) |
| >150 months | 37 | 74 (0–428) | 0.5 (0–3) | 3 (0–48) |
| p* | | | | |
| Pregnancies (n) | | | | |
| <2 | 26 | 131 (0–413) | 1.25 (0–2.88) | 3 (0–48) |
| 2 | 45 | 78 (0–428) | 0.62 (0–3) | 3 (0–40) |
| ≥3 | 39 | 145 (0–395) | 0.75 (0–2.63) | 4.5 (0–55) |
| p* | | | | |

SHS, Sharp score modification van der Heijde; Larsen, Larsen score for large joints (0–60); HAQ, Health Assessment Questionnaire.

*p Lowest versus highest tertile Mann-Whitney.
view was further strengthened by the finding that OC use had a protective role in the incidence of RA and also had a restraining influence on the course of the disease. In one study on hormone treatment in RA some improvement was reported in disease activity when oestrogen was given. In view of this evidence it was plausible that the long term outcome of RA might be influenced by female sex hormones. Our study, however, shows that hormonal parameters contribute only minimally to the explanation of long term radiological damage and disability.

This is the first prospective long term outcome study to investigate the association between hormonal factors and joint damage. One study reported the long term outcome in RA. In 1966 Oka described a retrospective case control study in a group of 100 consecutive patients who had been pregnant after the onset of RA. These women were compared with an equal number of women who had not been pregnant since developing RA. In that study, which comes of RA might be influenced by female sex hormones. Our view of this evidence it was plausible that the long term outcome in RA. Arthritis Rheum 1992;35:152–5.

In conclusion, this study shows that OC use and pregnancy do not significantly influence outcome in RA. There is, however, a trend for patients with multiple pregnancies and long term OC use to have less radiographic joint damage and a better functional level. This information is important in counselling young women with RA.

Authors’ affiliations
K W Drossaers-Bakker, Department of Rheumatology, Medisch Spectrum Twente, Enschede, The Netherlands
A H Zwinderman, Department of Medical Statistics, Leiden University Medical Centre, The Netherlands
D van Zeben, Department of Rheumatology, Reiner de Graaf Hospital, Delft, The Netherlands
F C Breedveld, Department of Rheumatology, Leiden University Medical Centre, The Netherlands
J M W Hazes, Department of Rheumatology, Erasmus University of Rotterdam, The Netherlands

REFERENCES
Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis

K W Drossaers-Bakker, A H Zwinderman, D van Zeben, F C Breedveld and J M W Hazes

Ann Rheum Dis 2002 61: 405-408
doi: 10.1136/ard.61.5.405

Updated information and services can be found at:
http://ard.bmj.com/content/61/5/405

These include:

References
This article cites 19 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/61/5/405#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Connective tissue disease (4253)
- Degenerative joint disease (4641)
- Immunology (including allergy) (5144)
- Musculoskeletal syndromes (4951)
- Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/